| News

BaseLaunch supports Switzerland as an innovation location

27.08.2019

Switzerland often receives awards for its innovative strength. Life sciences have generally played a huge part in this acclaim. The BaseLaunch accelerator operated by BaselArea.swiss is a major reason for innovation, a media report has found.

BaseLaunch

In its latest issue, the digital magazine “Pharma – Technology Focus” has dedicated an article to innovation in Switzerland. It explores the journey from startup to listed company and presents some of the success stories in the life sciences sector. The BaseLaunch accelerator operated by the innovation and economic promotion agency BaselArea.swiss is playing a key role in this development.

Almost two thirds of those in employed in the Swiss pharmaceutical sector work in the greater Basel area: 700 companies, more than 30,000 employees and R&D investment of 21 billion Swiss francs – these impressive figures are cited in the article. Industry activity is just one element of life sciences in Basel. The second is academic research, as director of BaseLaunch Stephan Emmerth explains, adding that more than 1,000 research groups and 13 research institutes are based in the region. Basel is therefore the perfect place for startups – and that’s where BaseLaunch comes into play.

The accelerator was founded in 2017 and is supported by the pharma giants Roche and Novartis. BaseLaunch helps startups launch and further develop their business models. This makes them attractive for venture capital funds and major pharma corporations, which invest as a result. “To do so, we offer grants of up to 250,000 francs and access to our partners,” said Stephan Emmerth. BaseLaunch has supported ten startups in this way to date, embedding them in the Basel area’s life sciences ecosystem.

In future, these companies could quite likely appear on the SIX Swiss Exchange. According to the magazine, SIX is the most important biotech exchange in Europe. The first major company from Basel to list on the exchange was Lonza in 1999 and Actelion a year later. After Johnson & Johnson took over Actelion, the spin-off Idorsia also decided to go public. They are considered pioneers, and the next company that follows in their footsteps could quite possibly have been helped on its way by BaseLaunch.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

VectivBio secures investments totaling 110 million dollars
Basel Area Business & Innovation, Innovation, Invest

VectivBio secures investments totaling 110 million dollars

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...

Read More
Polyphor receives up to 18 million dollars for development of antibiotics
Basel Area Business & Innovation, Innovation, Invest

Polyphor receives up to 18 million dollars for development of antibiotics

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...

Read More
What makes Switzerland’s economy resilient in face of COVID pandemic
Basel Area Business & Innovation, Invest

What makes Switzerland’s economy resilient in face of COVID pandemic

The COVID-19 pandemic has hit economies worldwide – and we have not yet overcome it. However, Switzerland is among the...

Read More
DayOne Accelerator applications open
Basel Area Business & Innovation, Innovation

DayOne Accelerator applications open

We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!

Read More
Matériaux Sabag printing concrete elements
Basel Area Business & Innovation, Innovation, Invest

Matériaux Sabag printing concrete elements

The Jura-based company Matériaux Sabag is now using a 3D printing solution to produce its concrete elements. This approach allows...

Read More
Six companies win the i4Challenge
Basel Area Business & Innovation, Innovation

Six companies win the i4Challenge

The i4Challenge expert jury has selected six winners from 18 finalists. The Industry 4.0 solutions range from 3D printing, IoT,...

Read More
Monte Rosa Therapeutics banks 96 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Monte Rosa Therapeutics banks 96 million US dollars

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...

Read More
Roche launches new coronavirus antibody test
Basel Area Business & Innovation, Innovation, Invest

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...

Read More
Investors see great potential in Polyneuron
Basel Area Business & Innovation, Innovation, Invest

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...

Read More
Lonza set to manufacture coronavirus drug for Humanigen
Basel Area Business & Innovation, Innovation, Invest

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.